Search

Your search keyword '"Mancini, V"' showing total 747 results
Start Over Author "Mancini, V"
747 results on '"Mancini, V"'

1. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

Author

Maurillo, L., Spagnoli, A., Candoni, A., Papayannidis, C., Borlenghi, E., Lazzarotto, D., Fianchi, L., Sciumè, M., Zannier, M.E., Buccisano, F., Del Principe, M.I., Mancini, V., Breccia, M., Fanin, R., Todisco, E., Lunghi, M., Palmieri, R., Fracchiolla, N., Musto, P., Rossi, G., and Venditti, A.

Published
2023
Full Text
View/download PDF

5. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

Author

Rossi, G, Borlenghi, E, Zappasodi, P, Lussana, F, Bernardi, M, Basilico, C, Molteni, A, Lotesoriere, I, Turrini, M, Frigeni, M, Fumagalli, M, Cozzi, P, Gigli, F, Cattaneo, C, Fracchiolla, N, Riva, M, Martini, G, Mancini, V, Cairoli, R, Todisco, E, Rossi, Giuseppe, Borlenghi, Erika, Zappasodi, Patrizia, Lussana, Federico, Bernardi, Massimo, Basilico, Claudia, Molteni, Alfredo, Lotesoriere, Ivana, Turrini, Mauro, Frigeni, Marco, Fumagalli, Monica, Cozzi, Paola, Gigli, Federica, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Riva, Marta, Martini, Gianluca, Mancini, Valentina, Cairoli, Roberto, Todisco, Elisabetta, Rossi, G, Borlenghi, E, Zappasodi, P, Lussana, F, Bernardi, M, Basilico, C, Molteni, A, Lotesoriere, I, Turrini, M, Frigeni, M, Fumagalli, M, Cozzi, P, Gigli, F, Cattaneo, C, Fracchiolla, N, Riva, M, Martini, G, Mancini, V, Cairoli, R, Todisco, E, Rossi, Giuseppe, Borlenghi, Erika, Zappasodi, Patrizia, Lussana, Federico, Bernardi, Massimo, Basilico, Claudia, Molteni, Alfredo, Lotesoriere, Ivana, Turrini, Mauro, Frigeni, Marco, Fumagalli, Monica, Cozzi, Paola, Gigli, Federica, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Riva, Marta, Martini, Gianluca, Mancini, Valentina, Cairoli, Roberto, and Todisco, Elisabetta

Abstract

A retrospective survey was conducted in hematologic centres of the Rete Ematologica Lombarda (REL) on 529 older AML patients seen between 2020–2022. Compared to 2008–2016, the use of intensive chemotherapy (ICT) decreased from 40% to 18.1% and of hypomethylating agents (HMAs) from 19.5% to 13%, whereas the combination of Venetoclax/HMA, initially not available, increased from 0% to 36.7%. Objective treatment-specific fitness criteria proposed by SIE/SIES/GITMO in 2013 allow an appropriate choice between ICT and HMAs by balancing their efficacy and toxicity. Venetoclax/HMA, registered for patients unfit to ICT, has a unique toxicity profile because of prolonged granulocytopenia and increased infectious risk. Aiming at defining specific fitness criteria for the safe use of Venetoclax/HMA, a preliminary investigation was conducted among expert REL hematologists, asking for modifications of SIE/SIES/GITMO criteria they used to select candidates for Venetoclax/HMA. While opinions among experts varied, a general consensus emerged on restricting SIE/SIES/GITMO criteria for ICT-unfit patients to an age limit of 80–85, cardiac function > 40%, and absence of recurrent lung infections, bronchiectasis, or exacerbating COPD. Also, the presence of an adequate caregiver was considered mandatory. Such expert opinions may be clinically useful and may be considered when treatment-specific fitness criteria are updated to include Venetoclax/HMA.

Published
2024

6. Myeloma’s multiple morphologies

Author

Cantoni, S, Galitzia, A, Mancini, V, Cafro, A, Cairoli, R, Cafro, AM, Cantoni, S, Galitzia, A, Mancini, V, Cafro, A, Cairoli, R, and Cafro, AM

Published
2024

7. Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management

Author

Cavazza, G, Motto, C, Regna-Gladin, C, Travi, G, Di Gennaro, E, Peracchi, F, Monti, B, Corti, N, Greco, R, Minga, P, Riva, M, Rimoldi, S, Vecchi, M, Rogati, C, Motta, D, Pazzi, A, Vismara, C, Bandiera, L, Crippa, F, Mancini, V, Sessa, M, Oltolini, C, Cairoli, R, Puoti, M, Cavazza, Gabriele, Motto, Cristina, Regna-Gladin, Caroline, Travi, Giovanna, Di Gennaro, Elisa, Peracchi, Francesco, Monti, Bianca, Corti, Nicolò, Greco, Rosa, Minga, Periana, Riva, Marta, Rimoldi, Sara, Vecchi, Marta, Rogati, Carlotta, Motta, Davide, Pazzi, Annamaria, Vismara, Chiara, Bandiera, Laura, Crippa, Fulvio, Mancini, Valentina, Sessa, Maria, Oltolini, Chiara, Cairoli, Roberto, Puoti, Massimo, Cavazza, G, Motto, C, Regna-Gladin, C, Travi, G, Di Gennaro, E, Peracchi, F, Monti, B, Corti, N, Greco, R, Minga, P, Riva, M, Rimoldi, S, Vecchi, M, Rogati, C, Motta, D, Pazzi, A, Vismara, C, Bandiera, L, Crippa, F, Mancini, V, Sessa, M, Oltolini, C, Cairoli, R, Puoti, M, Cavazza, Gabriele, Motto, Cristina, Regna-Gladin, Caroline, Travi, Giovanna, Di Gennaro, Elisa, Peracchi, Francesco, Monti, Bianca, Corti, Nicolò, Greco, Rosa, Minga, Periana, Riva, Marta, Rimoldi, Sara, Vecchi, Marta, Rogati, Carlotta, Motta, Davide, Pazzi, Annamaria, Vismara, Chiara, Bandiera, Laura, Crippa, Fulvio, Mancini, Valentina, Sessa, Maria, Oltolini, Chiara, Cairoli, Roberto, and Puoti, Massimo

Abstract

Central nervous system (CNS) lesions, especially invasive fungal diseases (IFDs), in immunocompromised patients pose a great challenge in diagnosis and treatment. We report the case of a 48-year-old man with acute myeloid leukaemia and probable pulmonary aspergillosis, who developed hyposthenia of the left upper limb, after achieving leukaemia remission and while on voriconazole. Magnetic resonance imaging (MRI) showed oedematous CNS lesions with a haemorrhagic component in the right hemisphere with lepto-meningitis. After 2 weeks of antibiotics and amphotericin-B, brain biopsy revealed chronic inflammation with abscess and necrosis, while cultures were negative. Clinical recovery was attained, he was discharged on isavuconazole and allogeneic transplant was postponed, introducing azacitidine as a maintenance therapy. After initial improvement, MRI worsened; brain biopsy was repeated, showing similar histology; and 16S metagenomics sequencing analysis was positive (Veilonella, Pseudomonas). Despite 1 month of meropenem, MRI did not improve. The computer tomography and PET scan excluded extra-cranial infectious–inflammatory sites, and auto-immune genesis (sarcoidosis, histiocytosis, CNS vasculitis) was deemed unlikely due to the histological findings and unilateral lesions. We hypothesised possible IFD with peri-lesion inflammation and methyl-prednisolone was successfully introduced. Steroid tapering is ongoing and isavuconazole discontinuation is planned with close follow-up. In conclusion, the management of CNS complications in immunocompromised patients needs an interdisciplinary approach.

Published
2024

8. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Author

Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), Foa R., Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), and Foa R.

Abstract

N/A

Published
2024

11. Microglia‐derived extracellular vesicles in homeostasis and demyelination/remyelination processes.

Author

Wies Mancini, V. S. B., Mattera, V. S., Pasquini, J. M., Pasquini, L. A., and Correale, J. D.

Subjects
*EXTRACELLULAR vesicles, *OLIGODENDROGLIA, *DEMYELINATION, *CENTRAL nervous system, *EXTRACELLULAR space, *MYELOID cells, *HOMEOSTASIS, *MEMBRANE lipids
Abstract

Microglia (MG) play a crucial role as the predominant myeloid cells in the central nervous system and are commonly activated in multiple sclerosis. They perform essential functions under normal conditions, such as actively surveying the surrounding parenchyma, facilitating synaptic remodeling, engulfing dead cells and debris, and protecting the brain against infectious pathogens and harmful self‐proteins. Extracellular vesicles (EVs) are diverse structures enclosed by a lipid bilayer that originate from intracellular endocytic trafficking or the plasma membrane. They are released by cells into the extracellular space and can be found in various bodily fluids. EVs have recently emerged as a communication mechanism between cells, enabling the transfer of functional proteins, lipids, different RNA species, and even fragments of DNA from donor cells. MG act as both source and recipient of EVs. Consequently, MG‐derived EVs are involved in regulating synapse development and maintaining homeostasis. These EVs also directly influence astrocytes, significantly increasing the release of inflammatory cytokines like IL‐1β, IL‐6, and TNF‐α, resulting in a robust inflammatory response. Furthermore, EVs derived from inflammatory MG have been found to inhibit remyelination, whereas Evs produced by pro‐regenerative MG effectively promote myelin repair. This review aims to provide an overview of the current understanding of MG‐derived Evs, their impact on neighboring cells, and the cellular microenvironment in normal conditions and pathological states, specifically focusing on demyelination and remyelination processes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. MIS-A: Beware of non-lymphoma

Author

Cantoni, S, Greco, R, Mancini, V, Russo, V, Capasso, A, Travi, G, Vanzulli, A, Cairoli, R, Cantoni, S, Greco, R, Mancini, V, Russo, V, Capasso, A, Travi, G, Vanzulli, A, and Cairoli, R

Subjects
Lymphoma, SARS-CoV-2, MIS-A
Published
2023

18. Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Author

Gatti, A, Veronese, S, Grillo, G, Di Camillo, B, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, Magliano, G, Stefanucci, M, Brando, B, Beghini, A, Cairoli, R, Gatti, Arianna, Veronese, Silvio, Grillo, Giovanni, Di Camillo, Barbara, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, Magliano, Gabriele, Stefanucci, Marta Rachele, Brando, Bruno, Beghini, Alessandro, Cairoli, Roberto, Gatti, A, Veronese, S, Grillo, G, Di Camillo, B, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, Magliano, G, Stefanucci, M, Brando, B, Beghini, A, Cairoli, R, Gatti, Arianna, Veronese, Silvio, Grillo, Giovanni, Di Camillo, Barbara, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, Magliano, Gabriele, Stefanucci, Marta Rachele, Brando, Bruno, Beghini, Alessandro, and Cairoli, Roberto

Published
2023

19. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, Todisco, Elisabetta, Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023

20. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience

Author

Fianchi, Luana, Guolo, F., Marchesi, F., Cattaneo, C., Gottardi, M., Restuccia, F., Candoni, A., Ortu La Barbera, E., Fazzi, R., Pasciolla, C., Finizio, O., Fracchiolla, N., Delia, M., Lessi, F., Dargenio, M., Bonuomo, V., Del Principe, M. I., Zappasodi, P., Picardi, M., Basilico, C., Piedimonte, M., Minetto, P., Giordano, A., Chiusolo, Patrizia, Prezioso, L., Buquicchio, C., Melillo, L. M. A., Zama, D., Farina, F., Mancini, V., Terrenato, I., Rondoni, M., Urbino, I., Tumbarello, Mario, Busca, A., Pagano, Livio, Fianchi L., Chiusolo P. (ORCID:0000-0002-1355-1587), Tumbarello M. (ORCID:0000-0002-9519-8552), Pagano L. (ORCID:0000-0001-8287-928X), Fianchi, Luana, Guolo, F., Marchesi, F., Cattaneo, C., Gottardi, M., Restuccia, F., Candoni, A., Ortu La Barbera, E., Fazzi, R., Pasciolla, C., Finizio, O., Fracchiolla, N., Delia, M., Lessi, F., Dargenio, M., Bonuomo, V., Del Principe, M. I., Zappasodi, P., Picardi, M., Basilico, C., Piedimonte, M., Minetto, P., Giordano, A., Chiusolo, Patrizia, Prezioso, L., Buquicchio, C., Melillo, L. M. A., Zama, D., Farina, F., Mancini, V., Terrenato, I., Rondoni, M., Urbino, I., Tumbarello, Mario, Busca, A., Pagano, Livio, Fianchi L., Chiusolo P. (ORCID:0000-0002-1355-1587), Tumbarello M. (ORCID:0000-0002-9519-8552), and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

In the present study, we aimed to evaluate the absolute risk of infection in the real-life setting of AML patients treated with CPX-351. The study included all patients with AML from 30 Italian hematology centers of the SEIFEM group who received CPX-351 from July 2018 to June 2021. There were 200 patients included. Overall, 336 CPX-351 courses were counted: all 200 patients received the first induction cycle, 18 patients (5%) received a second CPX-351 induction, while 86 patients (26%) proceeded with the first CPX-351 consolidation cycle, and 32 patients (10%) received a second CPX-351 consolidation. A total of 249 febrile events were recorded: 193 during the first or second induction, and 56 after the first or second consolidation. After the diagnostic work-up, 92 events (37%) were classified as febrile neutropenia of unknown origin (FUO), 118 (47%) were classifiable as microbiologically documented infections, and 39 (17%) were classifiable as clinically documented infections. The overall 30-day mortality rate was 14% (28/200). The attributable mortality–infection rate was 6% (15/249). A lack of response to the CPX-351 treatment was the only factor significantly associated with mortality in the multivariate analysis [p-value: 0.004, OR 0.05, 95% CI 0.01–0.39]. Our study confirms the good safety profile of CPX-351 in a real-life setting, with an incidence of infectious complications comparable to that of the pivotal studies; despite prolonged neutropenia, the incidence of fungal infections was low, as was infection-related mortality.

Published
2023

25. A multicenter italian study: the coexistent overactive-underactive bladder (COUB) syndrome

Author

Mancini, V., primary, Martino, L., additional, d’Altilia, N., additional, Annese, P., additional, Illiano, E., additional, Costantini, E., additional, Serati, M., additional, Li Marzi, V., additional, Greco, P., additional, Gubbiotti, M., additional, Giannantoni, A., additional, Balzarro, M., additional, Rubilotta, E., additional, Busetto, G.M., additional, Bettocchi, C., additional, Cormio, L., additional, and Carrieri, G., additional

Published
2022
Full Text
View/download PDF

26. “BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION”: NEITHER BURKITT-LYMPHOMA NOR DIFFUSE LARGE B-CELL LYMPHOMA. WHAT THE MICROENVIRONMENT TELLS US

Author

Del Corvo, M., primary, Sapienza, M., additional, Siciliano, M., additional, Tornambè, S., additional, Mazzara, S., additional, Granai, M., additional, Mundo, L., additional, Arcuri, F., additional, Mancini, V., additional, Ferrara, D., additional, Ott, G., additional, Siebert, Reiner, additional, Fend, L. Quintanilla, additional, Fend, F., additional, Pileri, S., additional, Lazzi, S., additional, and Leoncini, L., additional

Published
2022
Full Text
View/download PDF

27. EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA

Author

Siciliano, M., primary, Tornambè, S., additional, Del Corvo, M., additional, Granai, M., additional, Mundo, L., additional, Sapienza, M., additional, Arcuri, F., additional, Mancini, V., additional, Santi, R., additional, Di Stefano, G., additional, Marafioti, T., additional, Ott, G., additional, Siebert, R., additional, Fend, L. Quintanilla, additional, Fend, F., additional, Pileri, S., additional, Leoncini, L., additional, and Lazzi, S., additional

Published
2022
Full Text
View/download PDF

28. The inflammation of the prostate score: development of a novel histological classification of prostatic inflammation and its association with clinical outcomes

Author

Falagario, U.G., primary, Ninivaggi, A., additional, Guzzi, F., additional, d’Altilia, N., additional, Recchia, M., additional, Mancini, V., additional, Selvaggio, O., additional, Bettocchi, C., additional, Busetto, G.M., additional, Cormio, L., additional, Sanguedolce, F., additional, and Carrieri, G., additional

Published
2022
Full Text
View/download PDF

29. Compared efficacy of adjuvant intravesical BCG-TICE vs. BCG-RIVM for high-risk non-muscle invasive bladder cancer (NMIBC): a propensity score matched analysis

Author

Del Giudice, F., primary, Flammia, R.S., additional, Chung, B.I., additional, Maggi, M., additional, Sciarra, A., additional, Scornajenghi, C.M., additional, Asero, V., additional, Pandolfo, S.D., additional, Falagario, U.G., additional, D’Attila, N., additional, Mancini, V., additional, Chirico, M., additional, Cinelli, F., additional, Carrieri, G., additional, De Berardinis, E., additional, and Busetto, G.M., additional

Published
2022
Full Text
View/download PDF

30. Corrigendum: Exome Sequencing in BRCA1-2 Candidate Familias: The Contribution of Other Cancer Susceptibility Genes (Front. Oncol., (2021), 11, 10.3389/fonc.2021.649435)

Author

Doddato G., Doddato, G, Valentino, F, Giliberti, A, Papa, F, Tita, R, Bruno, L, Resciniti, S, Fallerini, C, Benetti, E, Palmieri, M, Mencarelli, M, Fabbiani, A, Bruttini, M, Orrico, A, Baldassarri, M, Fava, F, Lopergolo, D, Rizzo, C, Lamacchia, V, Mannucci, S, Pinto, A, Curro, A, Mancini, V, Mari, F, Renieri, A, Ariani, F, Doddato G., Valentino F., Giliberti A., Papa F. T., Tita R., Bruno L. P., Resciniti S., Fallerini C., Benetti E., Palmieri M., Mencarelli M. A., Fabbiani A., Bruttini M., Orrico A., Baldassarri M., Fava F., Lopergolo D., Rizzo C. L., Lamacchia V., Mannucci S., Pinto A. M., Curro A., Mancini V., Mari F., Renieri A., Ariani F., Doddato G., Doddato, G, Valentino, F, Giliberti, A, Papa, F, Tita, R, Bruno, L, Resciniti, S, Fallerini, C, Benetti, E, Palmieri, M, Mencarelli, M, Fabbiani, A, Bruttini, M, Orrico, A, Baldassarri, M, Fava, F, Lopergolo, D, Rizzo, C, Lamacchia, V, Mannucci, S, Pinto, A, Curro, A, Mancini, V, Mari, F, Renieri, A, Ariani, F, Doddato G., Valentino F., Giliberti A., Papa F. T., Tita R., Bruno L. P., Resciniti S., Fallerini C., Benetti E., Palmieri M., Mencarelli M. A., Fabbiani A., Bruttini M., Orrico A., Baldassarri M., Fava F., Lopergolo D., Rizzo C. L., Lamacchia V., Mannucci S., Pinto A. M., Curro A., Mancini V., Mari F., Renieri A., and Ariani F.

Abstract

In the original article, there was an error. Instead of “Whole Exome Sequencing” we want to change to “Exome Sequencing” throughout the manuscript. A correction has been made to the Title: Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes A correction has been made to the Abstract, phrase 3: By Exome Sequencing (ES) we analyzed a series of 200 individuals selected for genetic testing in BRCA1-2 genes according to the updated National Comprehensive Cancer Network (NCCN) guidelines. A correction has been made to Keywords: BRCA1, BRCA2, cancer susceptibility genes, HBOC, ES (Exome Sequencing)

Published
2021

31. Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes

Author

Doddato, G, Valentino, F, Giliberti, A, Papa, F, Tita, R, Bruno, L, Resciniti, S, Fallerini, C, Benetti, E, Palmieri, M, Mencarelli, M, Fabbiani, A, Bruttini, M, Orrico, A, Baldassarri, M, Fava, F, Lopergolo, D, Lo Rizzo, C, Lamacchia, V, Mannucci, S, Pinto, A, Curro, A, Mancini, V, Mari, F, Renieri, A, Ariani, F, Doddato G., Valentino F., Giliberti A., Papa F. T., Tita R., Bruno L. P., Resciniti S., Fallerini C., Benetti E., Palmieri M., Mencarelli M. A., Fabbiani A., Bruttini M., Orrico A., Baldassarri M., Fava F., Lopergolo D., Lo Rizzo C., Lamacchia V., Mannucci S., Pinto A. M., Curro A., Mancini V., Mari F., Renieri A., Ariani F., Doddato, G, Valentino, F, Giliberti, A, Papa, F, Tita, R, Bruno, L, Resciniti, S, Fallerini, C, Benetti, E, Palmieri, M, Mencarelli, M, Fabbiani, A, Bruttini, M, Orrico, A, Baldassarri, M, Fava, F, Lopergolo, D, Lo Rizzo, C, Lamacchia, V, Mannucci, S, Pinto, A, Curro, A, Mancini, V, Mari, F, Renieri, A, Ariani, F, Doddato G., Valentino F., Giliberti A., Papa F. T., Tita R., Bruno L. P., Resciniti S., Fallerini C., Benetti E., Palmieri M., Mencarelli M. A., Fabbiani A., Bruttini M., Orrico A., Baldassarri M., Fava F., Lopergolo D., Lo Rizzo C., Lamacchia V., Mannucci S., Pinto A. M., Curro A., Mancini V., Mari F., Renieri A., and Ariani F.

Abstract

Hereditary Breast and Ovarian Cancer (HBOC) syndrome is a condition in which the risk of breast and ovarian cancer is higher than in the general population. The prevalent pathogenesis is attributable to inactivating variants of the BRCA1-2 highly penetrant genes, however, other cancer susceptibility genes may also be involved. By Whole Exome Sequencing (WES) we analyzed a series of 200 individuals selected for genetic testing in BRCA1-2 genes according to the updated National Comprehensive Cancer Network (NCCN) guidelines. Analysis by MLPA was performed to detect large BRCA1-2 deletions/duplications. Focusing on BRCA1-2 genes, data analysis identified 11 cases with pathogenic variants (4 in BRCA1 and 7 in BRCA1-2) and 12 with uncertain variants (7 in BRCA1 and 5 in BRCA2). Only one case was found with a large BRCA1 deletion. Whole exome analysis allowed to characterize pathogenic variants in 21 additional genes: 10 genes more traditionally associated to breast and ovarian cancer (ATM, BRIP1, CDH1, PALB2, PTEN, RAD51C, and TP53) (5% diagnostic yield) and 11 in candidate cancer susceptibility genes (DPYD, ERBB3, ERCC2, MUTYH, NQO2, NTHL1, PARK2, RAD54L, and RNASEL). In conclusion, this study allowed a personalized risk assessment and clinical surveillance in an increased number of HBOC families and to broaden the spectrum of causative variants also to candidate “non-canonical” genes.

Published
2021

32. Validation of the 'fitness criteria' for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)

Author

Borlenghi, E, Pagani, C, Zappasodi, P, Bernardi, M, Basilico, C, Cairoli, R, Fracchiolla, N, Todisco, E, Turrini, M, Cattaneo, C, Da Via, M, Ciceri, F, Passamonti, F, Mancini, V, Sciume, M, Cerqui, E, Rossi, G, Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Via M, Ciceri F, Passamonti F, Mancini V, Sciume M, Cerqui E, Rossi G, Borlenghi, E, Pagani, C, Zappasodi, P, Bernardi, M, Basilico, C, Cairoli, R, Fracchiolla, N, Todisco, E, Turrini, M, Cattaneo, C, Da Via, M, Ciceri, F, Passamonti, F, Mancini, V, Sciume, M, Cerqui, E, Rossi, G, Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Via M, Ciceri F, Passamonti F, Mancini V, Sciume M, Cerqui E, and Rossi G

Abstract

Objectives: Treatment of older patients with acute myeloid leukemia (AML) is still controversial. To facilitate treatment decisions, the “fitness criteria” proposed by Ferrara et al. (Leukemia, 2013), including age > 75 years, performance status and comorbidities, were verified retrospectively in 699 patients with AML (419 de-novo, 280 secondary AML), diagnosed at 8 Hematological Centers (REL). Methods: Patients were categorized in FIT to intensive chemotherapy (i-T) (292, 42.5%), UNFIT to i-T (289, 42.1%), or unfit even to non-intensive therapy (non i-T) (FRAIL) (105, 15.3%). Biological characteristics and treatment actually received by patients [i-T, 274 patients (39.2%); non i-T, 134 (19.2%), best-supportive care (BSC), 291 (41.6%)] were recorded. Results: “Fitness criteria” were easily applicable in 98.1% of patients. Overall concordance between “fitness criteria” and treatment actually received by patients was high (79.4%), 76% in FIT, 82.7% in UNFIT and 80% in FRAIL patients. Fitness independently predicted survival (median survival: 10.9, 4.2 and 1.8 months in FIT, UNFIT and FRAIL patients, respectively; p = 0.000), as confirmed also by multivariate analysis. In FRAIL patients, survival with any treatment was no better than with BSC, in UNFIT non i-T was as effective as i-T and better than BSC, and in FIT patients i-T was better than non i-T or BSC. In addition, a non-adverse risk AML, an ECOG PS <2, and receiving any treatment other than BSC had a favorable effect on survival (p < 0.001). Conclusion: These simple “fitness criteria” applied at the time of diagnosis could facilitate, together with AML biologic risk evaluation, the choice of the most appropriate treatment intensity in older AML patients.

Published
2021

33. GENETIC LANDSCAPE AND CLONAL EVOLUTION PATTERNS OF CEBPA-DOUBLE-MUTATED ACUTE MYELOID LEUKEMIA BASED ON NEXT-GENERATION SEQUENCING: A SINGLE CENTER RETROSPECTIVE ANALYSIS

Author

Leuzzi, L, Mancini, V, Veronese, S, Motta, V, Nichelatti, M, Beghini, A, Cairoli, R, Leuzzi L, Mancini V, Veronese S, Motta V, Nichelatti M, Beghini A, Cairoli R, Leuzzi, L, Mancini, V, Veronese, S, Motta, V, Nichelatti, M, Beghini, A, Cairoli, R, Leuzzi L, Mancini V, Veronese S, Motta V, Nichelatti M, Beghini A, and Cairoli R

Published
2021

34. Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study

Author

Bertolini, F, Ostuzzi, G, Pievani, M, Aguglia, A, Bartoli, F, Bortolaso, P, Callegari, C, Caroleo, M, Carra, G, Corbo, M, D'Agostino, A, De Fazio, P, Magliocco, F, Martinotti, G, Ostinelli, E, Piccinelli, M, Tedeschi, F, Barbui, C, Boschello, F, Gastaldon, C, Mazzi, M, Nose, M, Papola, D, Perini, G, Piccoli, A, Purgato, M, Ruggeri, M, Terlizzi, S, Turrini, G, Raffaele, G, Cavallotti, S, Chirico, M, Ferrato, F, Limosani, I, Mastromo, D, Monzani, E, Porcellana, M, Restaino, F, Annese, P, Bolognesi, S, Cerretini, M, De Capua, A, Debolini, S, Del Zanna, M, Fargnoli, F, Giannini, A, Luccarelli, L, Lucii, C, Pierantozzi, E, Tozzi, F, Bardicchia, F, Cardamone, G, Facchi, E, Magnani, N, Soscia, F, Biancosino, B, Zotos, S, Giacomin, M, Pompei, F, Spano, M, Zonta, F, Buzzi, A, Calzolari, R, Caselli, I, Diurni, M, Giana, E, Ielmini, M, Milano, A, Poloni, N, Sani, E, Zizolfi, D, Alberini, G, Cazzamalli, S, Costantini, C, Di Caro, A, Paronelli, C, Piantanida, S, Alessandro, P, Barbanti, S, D'Ippolito, C, Gozzi, M, Moretti, V, Campese, O, Di Capro, L, di Giannantonio, M, Fiori, F, Lorusso, M, Mancini, V, Viceconte, D, Calandra, C, Luca, M, Signorelli, M, Suraniti, F, Balzarro, B, Boncompagni, G, Caretto, V, Emiliani, R, Lupoli, P, Menchetti, M, Rossi, E, Storbini, V, Tarricone, I, Terzi, L, Boso, M, Catania, C, De Paoli, G, Risaro, P, Aspesi, F, Bava, M, Bono, A, Brambilla, G, Castagna, G, Lucchi, S, Nava, R, Provenzi, M, Tabacchi, T, Tremolada, M, Verrengia, E, Barchiesi, M, Oriani, M, Pacetti, M, Ferro, M, Ghio, L, Beneduce, R, Laffranchini, L, Magni, L, Rossi, G, Tura, G, Addeo, L, Balletta, G, De Vivo, E, Di Benedetto, R, Parise, V, Carpiniello, B, Pinna, F, Pecile, D, Mattei, C, Bonavigo, T, Fabrici, E, Panarello, S, Peresson, G, Vitucci, C, Gardellin, F, Strizzolo, S, Cossetta, E, Fizzotti, C, Moretti, D, Di Gregorio, L, Sozzi, F, Colli, G, La Barbera, D, Laurenzi, S, Bertolini F., Ostuzzi G., Pievani M., Aguglia A., Bartoli F., Bortolaso P., Callegari C., Caroleo M., Carra G., Corbo M., D'Agostino A., De Fazio P., Magliocco F., Martinotti G., Ostinelli E. G., Piccinelli M. P., Tedeschi F., Barbui C., Boschello F., Gastaldon C., Mazzi M. A., Nose M., Papola D., Perini G., Piccoli A., Purgato M., Ruggeri M., Terlizzi S., Turrini G., Raffaele G., Cavallotti S., Chirico M., Ferrato F., Limosani I., Mastromo D., Monzani E., Porcellana M., Restaino F., Annese P. M., Bolognesi S., Cerretini M., De Capua A., Debolini S., Del Zanna M., Fargnoli F., Giannini A., Luccarelli L., Lucii C., Pierantozzi E., Tozzi F., Bardicchia F., Cardamone G., Facchi E., Magnani N., Soscia F., Biancosino B., Zotos S., Giacomin M., Pompei F., Spano M., Zonta F., Buzzi A., Calzolari R., Caselli I., Diurni M., Giana E., Ielmini M., Milano A., Poloni N., Sani E., Zizolfi D., Alberini G., Cazzamalli S., Costantini C., Di Caro A., Paronelli C., Piantanida S., Piccinelli M., Alessandro P., Barbanti S. V., D'Ippolito C., Gozzi M., Moretti V., Campese O., Di Capro L., di Giannantonio M., Fiori F., Lorusso M., Mancini V., Viceconte D., Calandra C., Luca M., Signorelli M. S., Suraniti F., Balzarro B., Boncompagni G., Caretto V., Emiliani R., Lupoli P., Menchetti M., Rossi E., Storbini V., Tarricone I., Terzi L., Boso M., Catania C., De Paoli G., Risaro P., Aspesi F., Bava M., Bono A., Brambilla G., Castagna G., Lucchi S., Nava R., Provenzi M., Tabacchi T., Tremolada M., Verrengia E., Barchiesi M., Oriani M. G., Pacetti M., Ferro M., Ghio L., Beneduce R., Laffranchini L., Magni L. R., Rossi G., Tura G. B., Addeo L., Balletta G., De Vivo E., Di Benedetto R., Parise V. F., Carpiniello B., Pinna F., Pecile D., Mattei C., Bonavigo T., Fabrici E. P., Panarello S., Peresson G., Vitucci C., Gardellin F., Strizzolo S., Cossetta E., Fizzotti C., Moretti D., Di Gregorio L., Sozzi F., Colli G., La Barbera D., Laurenzi S., Bertolini, F, Ostuzzi, G, Pievani, M, Aguglia, A, Bartoli, F, Bortolaso, P, Callegari, C, Caroleo, M, Carra, G, Corbo, M, D'Agostino, A, De Fazio, P, Magliocco, F, Martinotti, G, Ostinelli, E, Piccinelli, M, Tedeschi, F, Barbui, C, Boschello, F, Gastaldon, C, Mazzi, M, Nose, M, Papola, D, Perini, G, Piccoli, A, Purgato, M, Ruggeri, M, Terlizzi, S, Turrini, G, Raffaele, G, Cavallotti, S, Chirico, M, Ferrato, F, Limosani, I, Mastromo, D, Monzani, E, Porcellana, M, Restaino, F, Annese, P, Bolognesi, S, Cerretini, M, De Capua, A, Debolini, S, Del Zanna, M, Fargnoli, F, Giannini, A, Luccarelli, L, Lucii, C, Pierantozzi, E, Tozzi, F, Bardicchia, F, Cardamone, G, Facchi, E, Magnani, N, Soscia, F, Biancosino, B, Zotos, S, Giacomin, M, Pompei, F, Spano, M, Zonta, F, Buzzi, A, Calzolari, R, Caselli, I, Diurni, M, Giana, E, Ielmini, M, Milano, A, Poloni, N, Sani, E, Zizolfi, D, Alberini, G, Cazzamalli, S, Costantini, C, Di Caro, A, Paronelli, C, Piantanida, S, Alessandro, P, Barbanti, S, D'Ippolito, C, Gozzi, M, Moretti, V, Campese, O, Di Capro, L, di Giannantonio, M, Fiori, F, Lorusso, M, Mancini, V, Viceconte, D, Calandra, C, Luca, M, Signorelli, M, Suraniti, F, Balzarro, B, Boncompagni, G, Caretto, V, Emiliani, R, Lupoli, P, Menchetti, M, Rossi, E, Storbini, V, Tarricone, I, Terzi, L, Boso, M, Catania, C, De Paoli, G, Risaro, P, Aspesi, F, Bava, M, Bono, A, Brambilla, G, Castagna, G, Lucchi, S, Nava, R, Provenzi, M, Tabacchi, T, Tremolada, M, Verrengia, E, Barchiesi, M, Oriani, M, Pacetti, M, Ferro, M, Ghio, L, Beneduce, R, Laffranchini, L, Magni, L, Rossi, G, Tura, G, Addeo, L, Balletta, G, De Vivo, E, Di Benedetto, R, Parise, V, Carpiniello, B, Pinna, F, Pecile, D, Mattei, C, Bonavigo, T, Fabrici, E, Panarello, S, Peresson, G, Vitucci, C, Gardellin, F, Strizzolo, S, Cossetta, E, Fizzotti, C, Moretti, D, Di Gregorio, L, Sozzi, F, Colli, G, La Barbera, D, Laurenzi, S, Bertolini F., Ostuzzi G., Pievani M., Aguglia A., Bartoli F., Bortolaso P., Callegari C., Caroleo M., Carra G., Corbo M., D'Agostino A., De Fazio P., Magliocco F., Martinotti G., Ostinelli E. G., Piccinelli M. P., Tedeschi F., Barbui C., Boschello F., Gastaldon C., Mazzi M. A., Nose M., Papola D., Perini G., Piccoli A., Purgato M., Ruggeri M., Terlizzi S., Turrini G., Raffaele G., Cavallotti S., Chirico M., Ferrato F., Limosani I., Mastromo D., Monzani E., Porcellana M., Restaino F., Annese P. M., Bolognesi S., Cerretini M., De Capua A., Debolini S., Del Zanna M., Fargnoli F., Giannini A., Luccarelli L., Lucii C., Pierantozzi E., Tozzi F., Bardicchia F., Cardamone G., Facchi E., Magnani N., Soscia F., Biancosino B., Zotos S., Giacomin M., Pompei F., Spano M., Zonta F., Buzzi A., Calzolari R., Caselli I., Diurni M., Giana E., Ielmini M., Milano A., Poloni N., Sani E., Zizolfi D., Alberini G., Cazzamalli S., Costantini C., Di Caro A., Paronelli C., Piantanida S., Piccinelli M., Alessandro P., Barbanti S. V., D'Ippolito C., Gozzi M., Moretti V., Campese O., Di Capro L., di Giannantonio M., Fiori F., Lorusso M., Mancini V., Viceconte D., Calandra C., Luca M., Signorelli M. S., Suraniti F., Balzarro B., Boncompagni G., Caretto V., Emiliani R., Lupoli P., Menchetti M., Rossi E., Storbini V., Tarricone I., Terzi L., Boso M., Catania C., De Paoli G., Risaro P., Aspesi F., Bava M., Bono A., Brambilla G., Castagna G., Lucchi S., Nava R., Provenzi M., Tabacchi T., Tremolada M., Verrengia E., Barchiesi M., Oriani M. G., Pacetti M., Ferro M., Ghio L., Beneduce R., Laffranchini L., Magni L. R., Rossi G., Tura G. B., Addeo L., Balletta G., De Vivo E., Di Benedetto R., Parise V. F., Carpiniello B., Pinna F., Pecile D., Mattei C., Bonavigo T., Fabrici E. P., Panarello S., Peresson G., Vitucci C., Gardellin F., Strizzolo S., Cossetta E., Fizzotti C., Moretti D., Di Gregorio L., Sozzi F., Colli G., La Barbera D., and Laurenzi S.

Abstract

Background: Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Objective: Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. Methods: The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centres were assessed at baseline and at 6 and 12 months of follow-up. Psychopathology, drug attitude and treatment adherence were measured using the Brief Psychiatric Rating Scale, the Drug Attitude Inventory and the Kemp scale, respectively. Results: The study followed 394 participants for 12 months. The overall discontinuation rate at 12 months was 39.3% (95% confidence interval [CI] 34.4–44.3), with paliperidone LAI being the least discontinued LAI (33.9%; 95% CI 25.3–43.5) and olanzapine LAI the most discontinued (62.5%; 95% CI 35.4–84.8). The most frequent reason for discontinuation was onset of adverse events (32.9%; 95% CI 25.6–40.9) followed by participant refusal of the medication (20.6%; 95% CI 14.6–27.9). Medication adherence at baseline was negatively associated with discontinuation risk (hazard ratio [HR] 0.853; 95% CI 0.742–0.981; p = 0.026), whereas being prescribed olanzapine LAI was associated with increased discontinuation risk compared with being prescribed paliperidone LAI (HR 2.156; 95% CI 1.003–4.634; p = 0.049). Conclusions: Clinicians should be aware that LAI discontinuation is a frequent occurrence. LAI choice should be carefully discussed with the patient, tak

Published
2021

35. Dynamic in vitro culture of cryopreserved-thawed human ovarian cortical tissue using a microfluidics platform does not improve early folliculogenesis

Author

Valle, J.S. del, Mancini, V., Garay, M.L., Asseler, J.D., Fan, X.Y., Metzemaekers, J., Louwe, L.A., Pilgram, G.S.K., Westerlaken, L.A.J.V., Mello, N.M. van, Lopes, S.C.D.M., Obstetrics and Gynaecology, APH - Methodology, Obstetrics and gynaecology, Amsterdam Reproduction & Development, and Amsterdam Reproduction & Development (AR&D)

Subjects
ovarian cortical tissue, CORTEX, OOCYTES, fertility preservation, ANTI-MULLERIAN HORMONE, Endocrinology, Diabetes and Metabolism, secondary follicle, microfluidics, PRIMORDIAL FOLLICLES, cryopreservation, CANCER, folliculogenesis, DENSITY, CELLS, UNILAMINAR, SURVIVAL, GROWTH, follicular growth, human
Abstract

Current strategies for fertility preservation include the cryopreservation of embryos, mature oocytes or ovarian cortical tissue for autologous transplantation. However, not all patients that could benefit from fertility preservation can use the currently available technology. In this regard, obtaining functional mature oocytes from ovarian cortical tissue in vitro would represent a major breakthrough in fertility preservation as well as in human medically assisted reproduction. In this study, we have used a microfluidics platform to culture cryopreserved-thawed human cortical tissue for a period of 8 days and evaluated the effect of two different flow rates in follicular activation and growth. The results showed that this dynamic system supported follicular development up to the secondary stage within 8 days, albeit with low efficiency. Surprisingly, the stromal cells in the ovarian cortical tissue were highly sensitive to flow and showed high levels of apoptosis when cultured under high flow rate. Moreover, after 8 days in culture, the stromal compartment showed increase levels of collagen deposition, in particular in static culture. Although microfluidics dynamic platforms have great potential to simulate tissue-level physiology, this system still needs optimization to meet the requirements for an efficient in vitro early follicular growth.

Published
2022

36. Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study

Author

Bertolini, F., Ostuzzi, G., Pievani, M., Aguglia, A., Bartoli, F., Bortolaso, P., Callegari, C., Caroleo, M., Carra, G., Corbo, M., D'Agostino, A., De Fazio, P., Magliocco, F., Martinotti, G., Ostinelli, E. G., Piccinelli, M. P., Tedeschi, F., Barbui, C., Boschello, F., Gastaldon, C., Mazzi, M. A., Nose, M., Papola, D., Perini, G., Piccoli, A., Purgato, M., Ruggeri, M., Terlizzi, S., Turrini, G., Raffaele, G., Cavallotti, S., Chirico, M., Ferrato, F., Limosani, I., Mastromo, D., Monzani, E., Porcellana, M., Restaino, F., Annese, P. M., Bolognesi, S., Cerretini, M., De Capua, A., Debolini, S., Del Zanna, M., Fargnoli, F., Giannini, A., Luccarelli, L., Lucii, C., Pierantozzi, E., Tozzi, F., Bardicchia, F., Cardamone, G., Facchi, E., Magnani, N., Soscia, F., Biancosino, B., Zotos, S., Giacomin, M., Pompei, F., Spano, M., Zonta, F., Buzzi, A., Callegred, C., Calzolari, R., Caselli, I., Diurni, M., Giana, E., Ielmini, M., Milano, A., Poloni, N., Sani, E., Zizolfi, D., Alberini, G., Cazzamalli, S., Costantini, C., Di Caro, A., Paronelli, C., Piantanida, S., Piccinelli, M., Alessandro, P., Barbanti, S. V., D'Ippolito, C., Gozzi, M., Moretti, V., Campese, O., Di Capro, L., di Giannantonio, M., Fiori, F., Lorusso, M., Mancini, V., Viceconte, D., Calandra, C., Luca, M., Signorelli, M. S., Suraniti, F., Balzarro, B., Boncompagni, G., Caretto, V., Emiliani, R., Lupoli, P., Menchetti, M., Rossi, E., Storbini, V., Tarricone, I., Terzi, L., Boso, M., Catania, C., De Paoli, G., Risaro, P., Aspesi, F., Bava, M., Bono, A., Brambilla, G., Castagna, G., Lucchi, S., Nava, R., Provenzi, M., Tabacchi, T., Tremolada, M., Verrengia, E., Barchiesi, M., Oriani, M. G., Pacetti, M., Ferro, M., Ghio, L., Beneduce, R., Laffranchini, L., Magni, L. R., Rossi, G., Tura, G. B., Addeo, L., Balletta, G., De Vivo, E., Di Benedetto, R., Parise, V. F., Carpiniello, B., Pinna, F., Pecile, D., Mattei, C., Bonavigo, T., Fabrici, E. P., Panarello, S., Peresson, G., Vitucci, C., Gardellin, F., Strizzolo, S., Cossetta, E., Fizzotti, C., Moretti, D., Di Gregorio, L., Sozzi, F., Colli, G., La Barbera, D., Laurenzi, S., Bertolini, F, Ostuzzi, G, Pievani, M, Aguglia, A, Bartoli, F, Bortolaso, P, Callegari, C, Caroleo, M, Carra, G, Corbo, M, D'Agostino, A, De Fazio, P, Magliocco, F, Martinotti, G, Ostinelli, E, Piccinelli, M, Tedeschi, F, Barbui, C, Boschello, F, Gastaldon, C, Mazzi, M, Nose, M, Papola, D, Perini, G, Piccoli, A, Purgato, M, Ruggeri, M, Terlizzi, S, Turrini, G, Raffaele, G, Cavallotti, S, Chirico, M, Ferrato, F, Limosani, I, Mastromo, D, Monzani, E, Porcellana, M, Restaino, F, Annese, P, Bolognesi, S, Cerretini, M, De Capua, A, Debolini, S, Del Zanna, M, Fargnoli, F, Giannini, A, Luccarelli, L, Lucii, C, Pierantozzi, E, Tozzi, F, Bardicchia, F, Cardamone, G, Facchi, E, Magnani, N, Soscia, F, Biancosino, B, Zotos, S, Giacomin, M, Pompei, F, Spano, M, Zonta, F, Buzzi, A, Calzolari, R, Caselli, I, Diurni, M, Giana, E, Ielmini, M, Milano, A, Poloni, N, Sani, E, Zizolfi, D, Alberini, G, Cazzamalli, S, Costantini, C, Di Caro, A, Paronelli, C, Piantanida, S, Alessandro, P, Barbanti, S, D'Ippolito, C, Gozzi, M, Moretti, V, Campese, O, Di Capro, L, di Giannantonio, M, Fiori, F, Lorusso, M, Mancini, V, Viceconte, D, Calandra, C, Luca, M, Signorelli, M, Suraniti, F, Balzarro, B, Boncompagni, G, Caretto, V, Emiliani, R, Lupoli, P, Menchetti, M, Rossi, E, Storbini, V, Tarricone, I, Terzi, L, Boso, M, Catania, C, De Paoli, G, Risaro, P, Aspesi, F, Bava, M, Bono, A, Brambilla, G, Castagna, G, Lucchi, S, Nava, R, Provenzi, M, Tabacchi, T, Tremolada, M, Verrengia, E, Barchiesi, M, Oriani, M, Pacetti, M, Ferro, M, Ghio, L, Beneduce, R, Laffranchini, L, Magni, L, Rossi, G, Tura, G, Addeo, L, Balletta, G, De Vivo, E, Di Benedetto, R, Parise, V, Carpiniello, B, Pinna, F, Pecile, D, Mattei, C, Bonavigo, T, Fabrici, E, Panarello, S, Peresson, G, Vitucci, C, Gardellin, F, Strizzolo, S, Cossetta, E, Fizzotti, C, Moretti, D, Di Gregorio, L, Sozzi, F, Colli, G, La Barbera, D, Laurenzi, S, Bertolini F., Ostuzzi G., Pievani M., Aguglia A., Bartoli F., Bortolaso P., Callegari C., Caroleo M., Carra G., Corbo M., D'Agostino A., De Fazio P., Magliocco F., Martinotti G., Ostinelli E.G., Piccinelli M.P., Tedeschi F., Barbui C., Boschello F., Gastaldon C., Mazzi M.A., Nose M., Papola D., Perini G., Piccoli A., Purgato M., Ruggeri M., Terlizzi S., Turrini G., Raffaele G., Cavallotti S., Chirico M., Ferrato F., Limosani I., Mastromo D., Monzani E., Porcellana M., Restaino F., Annese P.M., Bolognesi S., Cerretini M., De Capua A., Debolini S., Del Zanna M., Fargnoli F., Giannini A., Luccarelli L., Lucii C., Pierantozzi E., Tozzi F., Bardicchia F., Cardamone G., Facchi E., Magnani N., Soscia F., Biancosino B., Zotos S., Giacomin M., Pompei F., Spano M., Zonta F., Buzzi A., Callegred C., Calzolari R., Caselli I., Diurni M., Giana E., Ielmini M., Milano A., Poloni N., Sani E., Zizolfi D., Alberini G., Cazzamalli S., Costantini C., Di Caro A., Paronelli C., Piantanida S., Piccinelli M., Alessandro P., Barbanti S.V., D'Ippolito C., Gozzi M., Moretti V., Campese O., Di Capro L., di Giannantonio M., Fiori F., Lorusso M., Mancini V., Viceconte D., Calandra C., Luca M., Signorelli M.S., Suraniti F., Balzarro B., Boncompagni G., Caretto V., Emiliani R., Lupoli P., Menchetti M., Rossi E., Storbini V., Tarricone I., Terzi L., Boso M., Catania C., De Paoli G., Risaro P., Aspesi F., Bava M., Bono A., Brambilla G., Castagna G., Lucchi S., Nava R., Provenzi M., Tabacchi T., Tremolada M., Verrengia E., Barchiesi M., Oriani M.G., Pacetti M., Ferro M., Ghio L., Beneduce R., Laffranchini L., Magni L.R., Rossi G., Tura G.B., Addeo L., Balletta G., De Vivo E., Di Benedetto R., Parise V.F., Carpiniello B., Pinna F., Pecile D., Mattei C., Bonavigo T., Fabrici E.P., Panarello S., Peresson G., Vitucci C., Gardellin F., Strizzolo S., Cossetta E., Fizzotti C., Moretti D., Di Gregorio L., Sozzi F., Colli G., La Barbera D., and Laurenzi S.

Subjects
Male, Pediatrics, respectively), 0302 clinical medicine, Delayed-Action Preparation, Brief Psychiatric Rating Scale, Pharmacology (medical), he STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in Italy, Original Research Article, Prospective Studies, Prospective cohort study, treatment, Mental Disorders, Hazard ratio, whereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5%, Psychiatric Status Rating Scale, Middle Aged, side efects, Psychiatry and Mental health, Italy, Mental Disorder, Female, he STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in Italy, occurring in almost 40% of the entire sample, side efects, participant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4%, respectively), whereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5%, respectively). In multivariate analysis, being prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation risk, Human, Antipsychotic Agents, medicine.drug, Psychopathology, Adult, medicine.medical_specialty, Discontinuation, Follow-Up Studie, Medication Adherence, 03 medical and health sciences, medicine, Humans, Paliperidone, Adverse effect, Settore MED/25 - Psichiatria, discontinuation rates, Psychiatric Status Rating Scales, respectively). In multivariate analysis, business.industry, Long-Acting Antipsychotic, long-acting injectable antipsychotics, Survival Analysis, Confidence interval, participant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4%, 030227 psychiatry, Prospective Studie, Antipsychotic Agent, occurring in almost 40% of the entire sample, Delayed-Action Preparations, Neurology (clinical), business, 030217 neurology & neurosurgery, being prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation risk, Follow-Up Studies
Abstract

Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Objective Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. Methods The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centres were assessed at baseline and at 6 and 12 months of follow-up. Psychopathology, drug attitude and treatment adherence were measured using the Brief Psychiatric Rating Scale, the Drug Attitude Inventory and the Kemp scale, respectively. Results The study followed 394 participants for 12 months. The overall discontinuation rate at 12 months was 39.3% (95% confidence interval [CI] 34.4–44.3), with paliperidone LAI being the least discontinued LAI (33.9%; 95% CI 25.3–43.5) and olanzapine LAI the most discontinued (62.5%; 95% CI 35.4–84.8). The most frequent reason for discontinuation was onset of adverse events (32.9%; 95% CI 25.6–40.9) followed by participant refusal of the medication (20.6%; 95% CI 14.6–27.9). Medication adherence at baseline was negatively associated with discontinuation risk (hazard ratio [HR] 0.853; 95% CI 0.742–0.981; p = 0.026), whereas being prescribed olanzapine LAI was associated with increased discontinuation risk compared with being prescribed paliperidone LAI (HR 2.156; 95% CI 1.003–4.634; p = 0.049). Conclusions Clinicians should be aware that LAI discontinuation is a frequent occurrence. LAI choice should be carefully discussed with the patient, taking into account individual characteristics and possible obstacles related to the practicalities of each formulation. Supplementary Information The online version contains supplementary material available at 10.1007/s40263-021-00809-w.

Published
2021

37. 70 PELVIC ORGAN PROLAPSE SURGERY: COMPARISON OF SACROCOLPOPEXY VERSUS LATERAL COLPOSUSPENSION

Author

Pagliarulo, V, primary, d’Altilia, N, additional, Martino, L, additional, Falagario, U, additional, Annese, P, additional, Busetto, G, additional, Bettocchi, C, additional, Martinello, R, additional, Manservigi, M, additional, Scutiero, G, additional, Bernardi, G, additional, Santi, E, additional, Cremonini, G, additional, Balzarro, M, additional, Cormio, L, additional, Carrieri, G, additional, and Mancini, V, additional

Published
2022
Full Text
View/download PDF

38. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19

Author

Cattaneo, C, Daffini, R, Pagani, C, Salvetti, M, Mancini, V, Borlenghi, E, D'Adda, M, Oberti, M, Paini, A, De Ciuceis, C, Barbullushi, K, Cancelli, V, Belotti, A, Re, A, Motta, M, Peli, A, Bianchetti, N, Anastasia, A, Dalceggio, D, Roccaro, A, Tucci, A, Cairoli, R, Muiesan, M, Rossi, G, Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G, Cattaneo, C, Daffini, R, Pagani, C, Salvetti, M, Mancini, V, Borlenghi, E, D'Adda, M, Oberti, M, Paini, A, De Ciuceis, C, Barbullushi, K, Cancelli, V, Belotti, A, Re, A, Motta, M, Peli, A, Bianchetti, N, Anastasia, A, Dalceggio, D, Roccaro, A, Tucci, A, Cairoli, R, Muiesan, M, Rossi, G, Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, and Rossi G

Abstract

Background: Patients with cancer are considered highly vulnerable to the recent coronavirus disease 2019 (COVID-19) pandemic. However, there are still few data on COVID-19 occurring in hematologic patients. Methods: One hundred two patients with COVID-19 symptoms and a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 seen at 2 hematologic departments located in Lombardy, Italy, during March 2020 were studied. Risk factors for acquiring COVID-19 were analyzed by comparisons of patients with COVID-19 and the standard hematologic population managed at the same institutions in 2019. Thirty-day survival was compared with the survival of matched uninfected control patients with similar hematologic disorders and nonhematologic patients affected by COVID-19. Results: Male sex was significantly more prevalent in patients with COVID-19. The infection occurred across all different types of hematologic disease; however, the risk of acquiring a COVID-19 infection was lower for patients with chronic myeloproliferative neoplasms, including chronic myeloid leukemia, and higher for patients with immune-mediated anemia on immunosuppressive-related treatments. The 30-day mortality rate was 39.2%, which was higher than the rates for nonhematologic patients with COVID-19 (23.5%; P =.02) and uninfected hematologic controls (3%; P <.001). The severity of the respiratory syndrome at presentation and active hematologic treatment were independently associated with a worse prognosis. Neither diagnosis nor disease status affected the prognosis. The worst prognosis was demonstrated among patients on active hematologic treatment and those with more severe respiratory syndrome at COVID-19 presentation. Conclusions: During the COVID-19 pandemic, patients should be advised to seek medical attention at the earliest signs of dyspnea and/or respiratory infection. Physicians should perform a risk-benefit analysis to determine the impact of temporarily deferring nonlif

Published
2020

39. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings from the STAR Network Depot Study

Author

Barbui C, Nosè M, Purgato M, Turrini G, Ostuzzi G, Mazzi MA, Papola D, Gastaldon C, Terlizzi S, Bertolini F, Piccoli A, Ruggeri M, De Fazio P, Magliocco F, Caroleo M, Raffaele G, D'Agostino A, Ostinelli EG, Chirico M, Cavallotti S, Lucii C, Bolognesi S, Debolini S, Pierantozzi E, Fargnoli F, Del Zanna M, Giannini A, Luccarelli L, De Capua A, Annese PM, Cerretini M, Tozzi F, Magnani N, Cardamone G, Bardicchia F, Facchi E, Soscia F, Zotos S, Biancosino B, Zonta F, Pompei F, Callegari C, Zizolfi D, Poloni N, Ielmini M, Caselli I, Giana E, Buzzi A, Diurni M, Milano A, Sani E, Calzolari R, Bortolaso P, Piccinelli M, Cazzamalli S, Alberini G, Piantanida S, Costantini C, Paronelli C, Di Caro A, Moretti V, Gozzi M, D'Ippolito C, Barbanti SV, Papalini A, Corbo M, Martinotti G, Campese O, Fiori F, Lorusso M, Di Capro L, Viceconte D, Mancini V, Suraniti F, Signorelli MSI, Rossi E, Lupoli P, Menchetti M, Terzi L, Boso M, Risaro P, De Paoli G, Catania C, Tarricone I, Caretto V, Storbini V, Emiliani R, Balzarro B, Carrà G, Bartoli F, Tabacchi T, Nava R, Bono A, Provenzi M, Brambilla G, Aspesi F, Trotta G, Tremolada M, Castagna G, Bava M, Verrengia E, Lucchi S, Oriani MG, Barchiesi M, Pacetti M, Aguglia A, Magni LR, Rossi G, Beneduce R, Tura GB, Laffranchini L, Mastromo D, Ferrato F, Restaino F, Monzani E, Porcellana M, Limosani I, Ghio L, Ferro M, Parise VF, Balletta G, Addeo L, De Vivo E, Di Benedetto R, Pinna F, Carpiniello B, Spano M, Giacomin M, Pecile D, Mattei C, Fabrici EP, Panarello S, Peresson G, Vitucci C, Bonavigo T, Perini G, Boschello F, Strizzolo S, Gardellin F, Di Giannantonio M, Moretti D, Fizzotti C, Cossetta E, Di Gregorio L, Sozzi F, Boncompagni G, La Barbera D, Colli G, Laurenzi S, Calandra C, Luca M, Crocamo C, STAR Network Depot Investigators, Bartoli F., Ostuzzi G., Crocamo C., Corbo M., D'Agostino A., Martinotti G., Ostinelli E.G., Tabacchi T., Barbui C., Carr G., Nose M., Purgato M., Turrini G., Mazzi M.A., Papola D., Gastaldon C., Terlizzi S., Bertolini F., Piccoli A., Ruggeri M., De Fazio P., Magliocco F., Caroleo M., Raffaele G., Chirico M., Cavallotti S., Lucii C., Bolognesi S., Debolini S., Pierantozzi E., Fargnoli F., Del Zanna M., Giannini A., Luccarelli L., De Capua A., Annese P.M., Cerretini M., Tozzi F., Magnani N., Cardamone G., Bardicchia F., Facchi E., Soscia F., Zotos S., Biancosino B., Zonta F., Pompei F., Callegari C., Zizolfi D., Poloni N., Ielmini M., Caselli I., Giana E., Buzzi A., Diurni M., Milano A., Sani E., Calzolari R., Bortolaso P., Piccinelli M., Cazzamalli S., Alberini G., Piantanida S., Costantini C., Paronelli C., Di Caro A., Moretti V., Gozzi M., D'Ippolito C., Barbanti S.V., Papalini A., Campese O., Fiori F., Lorusso M., Di Capro L., Viceconte D., Mancini V., Suraniti F., Signorelli M.S., Rossi E., Lupoli P., Menchetti M., Terzi L., Boso M., Risaro P., De Paoli G., Catania C., Tarricone I., Caretto V., Storbini V., Emiliani R., Balzarro B., Carra G., Nava R., Bono A., Provenzi M., Brambilla G., Aspesi F., Trotta G., Tremolada M., Castagna G., Bava M., Verrengia E., Lucchi S., Oriani M.G., Barchiesi M., Pacetti M., Aguglia A., Magni L.R., Rossi G., Beneduce R., Tura G.B., Laffranchini L., Mastromo D., Ferrato F., Restaino F., Monzani E., Porcellana M., Limosani I., Ghio L., Ferro M., Parise V.F., Balletta G., Addeo L., De Vivo E., Di Benedetto R., Pinna F., Carpiniello B., Spano M., Giacomin M., Pecile D., Mattei C., Fabrici E.P., Panarello S., Peresson G., Vitucci C., Bonavigo T., Perini G., Boschello F., Strizzolo S., Gardellin F., Di Giannantonio M., Moretti D., Fizzotti C., Cossetta E., Di Gregorio L., Sozzi F., Boncompagni G., La Barbera D., Colli G., Laurenzi S., Calandra C., Luca M., Barbui C, Nosè M, Purgato M, Turrini G, Ostuzzi G, Mazzi MA, Papola D, Gastaldon C, Terlizzi S, Bertolini F, Piccoli A, Ruggeri M, De Fazio P, Magliocco F, Caroleo M, Raffaele G, D'Agostino A, Ostinelli EG, Chirico M, Cavallotti S, Lucii C, Bolognesi S, Debolini S, Pierantozzi E, Fargnoli F, Del Zanna M, Giannini A, Luccarelli L, De Capua A, Annese PM, Cerretini M, Tozzi F, Magnani N, Cardamone G, Bardicchia F, Facchi E, Soscia F, Zotos S, Biancosino B, Zonta F, Pompei F, Callegari C, Zizolfi D, Poloni N, Ielmini M, Caselli I, Giana E, Buzzi A, Diurni M, Milano A, Sani E, Calzolari R, Bortolaso P, Piccinelli M, Cazzamalli S, Alberini G, Piantanida S, Costantini C, Paronelli C, Di Caro A, Moretti V, Gozzi M, D'Ippolito C, Barbanti SV, Papalini A, Corbo M, Martinotti G, Campese O, Fiori F, Lorusso M, Di Capro L, Viceconte D, Mancini V, Suraniti F, Signorelli MSI, Rossi E, Lupoli P, Menchetti M, Terzi L, Boso M, Risaro P, De Paoli G, Catania C, Tarricone I, Caretto V, Storbini V, Emiliani R, Balzarro B, Carrà G, Bartoli F, Tabacchi T, Nava R, Bono A, Provenzi M, Brambilla G, Aspesi F, Trotta G, Tremolada M, Castagna G, Bava M, Verrengia E, Lucchi S, Oriani MG, Barchiesi M, Pacetti M, Aguglia A, Magni LR, Rossi G, Beneduce R, Tura GB, Laffranchini L, Mastromo D, Ferrato F, Restaino F, Monzani E, Porcellana M, Limosani I, Ghio L, Ferro M, Parise VF, Balletta G, Addeo L, De Vivo E, Di Benedetto R, Pinna F, Carpiniello B, Spano M, Giacomin M, Pecile D, Mattei C, Fabrici EP, Panarello S, Peresson G, Vitucci C, Bonavigo T, Perini G, Boschello F, Strizzolo S, Gardellin F, Di Giannantonio M, Moretti D, Fizzotti C, Cossetta E, Di Gregorio L, Sozzi F, Boncompagni G, La Barbera D, Colli G, Laurenzi S, Calandra C, Luca M, Crocamo C, STAR Network Depot Investigators, Bartoli, F, Ostuzzi, G, Crocamo, C, Corbo, M, D'Agostino, A, Martinotti, G, Ostinelli, E, Tabacchi, T, Barbui, C, and Carra, G

Subjects
Aripiprazole monohydrate, Long-acting injectable antipsychotics, Paliperidone palmitate, Schizophrenia, Adult, Antipsychotic Agents, Aripiprazole, Female, Health Knowledge, Attitudes, Practice, Humans, Male, Medication Adherence, Paliperidone Palmitate, Practice Patterns, Physicians', Schizophrenic Psychology, Young Adult, Long-acting injectable antipsychotic, medicine.medical_specialty, medicine.medical_treatment, Aripiprazole monohydrate, Long-acting injectable antipsychotics, Paliperidone palmitate, Schizophrenia, Practice Patterns, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Brief Psychiatric Rating Scale, medicine, Pharmacology (medical), Antipsychotic, Settore MED/25 - Psichiatria, Practice, Physicians', business.industry, Health Knowledge, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Attitudes, Propensity score matching, Observational study, business, 030217 neurology & neurosurgery, medicine.drug, Psychopathology
Abstract

This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydrate). Individuals were comparable in terms of age, gender, treatment years, recent hospitalizations, previous long-acting injectable antipsychotic treatments, additional oral treatments, attitude toward drugs, medication adherence, and alcohol/substance-related comorbidities. Subjects starting PP1M presented higher BPRS overall (P = 0.009), positive (P = 0.015), and negative (P = 0.010) symptom scores compared to subjects starting aripiprazole monohydrate. Results were confirmed by appropriate regression models and propensity score matching analysis. No differences were found comparing the other BPRS subscale scores: affect, resistance, and activation. Clinicians may be more prone to prescribe PPM1, rather than aripiprazole monohydrate, to subjects showing higher overall symptom severity, including positive and negative symptoms. No additional clinical factors influenced prescribing attitudes in our sample.

Published
2020

40. Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Author

Cairoli, R, Gatti, A, Grillo, G, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, De Marco, B, Stefanucci, M, Brando, B, Veronese, S, Beghini, A, Stefanucci, MR, Veronese, SM, Cairoli, R, Gatti, A, Grillo, G, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, De Marco, B, Stefanucci, M, Brando, B, Veronese, S, Beghini, A, Stefanucci, MR, and Veronese, SM

Published
2022

41. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey

Author

Del Principe, M. I., Dragonetti, Giulia, Conti, A., Verga, L., Ballanti, S., Fanci, R., Candoni, A., Marchesi, F., Cattaneo, C., Lessi, F., Fracchiolla, N., Spolzino, A., Prezioso, L., Delia, M., Potenza, L., Decembrino, N., Castagnola, C., Nadali, G., Picardi, M., Zama, D., Orciulo, E., Veggia, B., Garzia, M., Dargenio, M., Melillo, L., Manetta, S., Russo, D., Mancini, V., Piedimonte, M., Tisi, M. C., Toschi, N., Busca, A., Pagano, Livio, Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Del Principe, M. I., Dragonetti, Giulia, Conti, A., Verga, L., Ballanti, S., Fanci, R., Candoni, A., Marchesi, F., Cattaneo, C., Lessi, F., Fracchiolla, N., Spolzino, A., Prezioso, L., Delia, M., Potenza, L., Decembrino, N., Castagnola, C., Nadali, G., Picardi, M., Zama, D., Orciulo, E., Veggia, B., Garzia, M., Dargenio, M., Melillo, L., Manetta, S., Russo, D., Mancini, V., Piedimonte, M., Tisi, M. C., Toschi, N., Busca, A., Pagano, Livio, Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

Background: In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP). The aims of this multicentre retrospective ‘SEIFEM 2016-B’ study were as follows: (1) to evaluate the current rate and the outcome of proven/probable IA and (2) to assess the efficacy of AP, in a large ‘real life’ series of patient with R/R AML submitted to salvage chemotherapy. Results: Of 2250 R/R AML patients, a total of 74 cases of IA (5.1%) were recorded as follows: 10 (0.7%) proven and 64 (4.3%) probable. Information about AP were available in 73/74 (99%) patients. Fifty-eight (79%) breakthrough infections occurred, mainly during AP with posaconazole [25 (43%)]. The patients who received AP during salvage chemotherapy showed a benefit from antifungal therapy (AT) than patients who did not received AP [43 (86%) vs 7 (14%); p <.033]. In a multivariate analysis, AP and absence of severe mucositis had a significant favourable effect on overall response rate. Conclusion: Our data demonstrated that the incidence of IA during the salvage chemotherapy is similar to the past. Nevertheless, the attributable mortality rate (AMR) appears to be lower than that previously reported in R/R AML. Further prospective studies should be performed to confirm our preliminary observation and understand and the why a decreased AMR is reported in this setting of high-risk patients.

Published
2022

42. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Author

Chiaretti, S., Bonifacio, M., Agrippino, R., Giglio, F., Annunziata, M., Curti, A., Del Principe, M. I., Salutari, P., Sciume, M., Delia, M., Armenio, M., Mancini, V., Mule, A., Grimaldi, F., Rege-Cambrin, G., Santoro, L., Lussana, F., Chiusolo, Patrizia, Pasciolla, C., Scattolin, A. M., Cerrano, M., Ciccone, M., Defina, M., Forghieri, F., Mazzone, C., Piccini, M., Ferrara, F., Pizzolo, G., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Chiaretti, S., Bonifacio, M., Agrippino, R., Giglio, F., Annunziata, M., Curti, A., Del Principe, M. I., Salutari, P., Sciume, M., Delia, M., Armenio, M., Mancini, V., Mule, A., Grimaldi, F., Rege-Cambrin, G., Santoro, L., Lussana, F., Chiusolo, Patrizia, Pasciolla, C., Scattolin, A. M., Cerrano, M., Ciccone, M., Defina, M., Forghieri, F., Mazzone, C., Piccini, M., Ferrara, F., Pizzolo, G., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

N/A

Published
2022

44. Probing morphological, genetic and metabolomic changes of in vitro embryo development in a microfluidic device

Author

Mancini, V, McKeegan, PJ, Schrimpe‐Rutledge, AC, Codreanu, SG, Sherrod, SD, McLean, JA, Picton, HM, and Pensabene, V

Subjects
animal structures, embryonic structures
Abstract

Assisted reproduction technologies for clinical and research purposes rely on a brief in vitro embryo culture which, despite decades of progress, remain suboptimal in comparison to the physiological environment. One promising tool to improve this technique is the development of bespoke microfluidic chambers. Here we present and validate a new microfluidic device in polydimethylsiloxane (PDMS) for the culture of early mouse embryos. Device material and design resulted embryo compatible and elicit minimal stress. Blastocyst formation, hatching, attachment and outgrowth formation on fibronectin-coated devices were similar to traditional microdrop methods. Total blastocyst cell number and allocation to the trophectoderm and inner cell mass lineages were unaffected. The devices were designed for culture of 10-12 embryos. Development rates, mitochondrial polarisation and metabolic turnover of key energy substrates glucose, pyruvate and lactate were consistent with groups of 10 embryos in microdrop controls. Increasing group size to 40 embryos per device was associated with increased variation in development rates and altered metabolism. Device culture did not perturb blastocyst gene expression but did elicit changes in embryo metabolome, which can be ascribed to substrate leaching from PDMS and warrant further investigation.

Published
2021

48. Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda”

Author

Mancini, V, Borlenghi, E, Leuzzi, L, Basilico, C, Bernardi, M, Zappasodi, P, Fumagalli, M, Todisco, E, Cattaneo, C, Lussana, F, Bertani, G, Ravelli, E, Fracchiolla, N, Turrini, M, Rossi, G, Cantoni, S, Cairoli, R, Mancini V., Borlenghi E., Leuzzi L., Basilico C., Bernardi M., Zappasodi P., Fumagalli M., Todisco E., Cattaneo C., Lussana F., Bertani G., Ravelli E., Fracchiolla N., Turrini M., Rossi G., Cantoni S., Cairoli R, Mancini, V, Borlenghi, E, Leuzzi, L, Basilico, C, Bernardi, M, Zappasodi, P, Fumagalli, M, Todisco, E, Cattaneo, C, Lussana, F, Bertani, G, Ravelli, E, Fracchiolla, N, Turrini, M, Rossi, G, Cantoni, S, Cairoli, R, Mancini V., Borlenghi E., Leuzzi L., Basilico C., Bernardi M., Zappasodi P., Fumagalli M., Todisco E., Cattaneo C., Lussana F., Bertani G., Ravelli E., Fracchiolla N., Turrini M., Rossi G., Cantoni S., and Cairoli R

Published
2019

49. Acute leukemia and high-risk myelodysplastic syndromes in hiv positive patients: 25-years' experience of the rete ematologica lombarda (REL)

Author

Cattaneo, C, Bernardi, M, Mancini, V, Pagani, C, Fumagalli, M, Zappasodi, P, Borlenghi, E, Re, A, Ciceri, F, Sciumé, M, Cairoli, R, Rossi, G, Cattaneo C., Bernardi M., Mancini V., Pagani C., Fumagalli M., Zappasodi P., Borlenghi E., Re A., Ciceri F., Sciumé M., Cairoli R, Rossi G, Cattaneo, C, Bernardi, M, Mancini, V, Pagani, C, Fumagalli, M, Zappasodi, P, Borlenghi, E, Re, A, Ciceri, F, Sciumé, M, Cairoli, R, Rossi, G, Cattaneo C., Bernardi M., Mancini V., Pagani C., Fumagalli M., Zappasodi P., Borlenghi E., Re A., Ciceri F., Sciumé M., Cairoli R, and Rossi G

Published
2019

50. Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Author

Cairoli R, Krampera M, Zappasodi P, Todisco E, Borlenghi E, Molteni A, Fumagalli M, Ubezio M, Bernardi M, Greco Ravelli, E (Ravelli, Erika), Mancini V, Grillo G, Riva M, De Marco B, Cassaro A, Brando B, Gatti A, Veronese SM, Beghini A, Cairoli, R, Krampera, M, Zappasodi, P, Todisco, E, Borlenghi, E, Molteni, A, Fumagalli, M, Ubezio, M, Bernardi, M, Greco, R, E,, Erika), Mancini, V, Grillo, G, Riva, M, De Marco, B, Cassaro, A, Brando, B, Gatti, A, Veronese, S, and Beghini, A

Subjects
medicine.medical_specialty, business.industry, Immunology, Phases of clinical research, Consolidation Chemotherapy, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, chemistry.chemical_compound, Regimen, chemistry, Maintenance therapy, Internal medicine, Cytarabine, Medicine, Midostaurin, business, Adverse effect, medicine.drug
Abstract

Genetic and Clinical Background: The clinical outcome of Core Binding Factor Leukemia (CBFL) seems influenced by the mutational status of KIT. In fact, several retrospective studies, in addition to our own, as well as a systematic review, indicate that KIT mutations have a negative prognostic impact in AML with t(8;21) or, to a lesser extent, with inv(16)/t(16;16). In addition, gene expression studies found KIT to be highly expressed in CBFL regardless of its mutational status. Furthermore, recent studies have identified novel recurrent somatic mutations co-occurring with KITmut. In-vitro studies revealed that Midostaurin (Mido) is effective in inhibiting both wild type (WT) and a range of KIT mutants. In addition, it is proven to be effective in KIT-positive malignancies such as Aggressive Systemic Mastocytosis (ASM), Mast Cell Leukemia (MCL), and SM with Associated Hematological Neoplasm (SM-AHN). With this background, we designed a Phase II trial to evaluate the safety and efficacy of Mido in association with Intensive Chemotherapy (IC), in CBFL regardless of KIT mutational status. Methods: The inclusion criteria were the following: age 18 to 60 years, diagnosis of de-novo CBFL, adequate organ function, signed informed consent. The exclusion criteria were: central nervous system involvement, uncontrolled infections, other active malignancies, a Qtc value greater than 470 ms (according to Bazett formula) at the electrocardiogram, significant uncontrolled or active cardiovascular diseases. Patients received standard induction therapy with an anthracycline containing regimen ("7+3"-like) + Mido, three cycles of post-remission consolidation chemotherapy with high-dose cytarabine + Mido, and 12 months of Mido as Maintenance. The Mido dosage was: 50 mg orally twice a day, on days 8-21, in association with IC, and 50 mg orally twice a day as single agent maintenance. In order to attain a reduction in 2 years Relapse Incidence (RI), from the historical value of 48% to 28% (Primary Objective of the Study), we plan to enrol 39 patients (power 82%, alpha error 4,6%). At diagnosis all patients were studied by a comprehensive NGS panel targeting 40 DNA genes and 29 RNA fusion driver genes. MRD status was assessed by qPCR and high-resolution multicolor flow cytometry at established check-points during consolidation and maintenance therapy. Results: 17 patients were enrolled between December 2018 to April 2020 (table1). Overall, the CR rate was 94.2%. At a median follow-up of 9 months (range 3-19 months), we recorded a RI of 12.5%, an OS of 93.7%, and a DFS of 81.2%. 16 patients continue on study and 14 patients are in 1st CR, MRD-negative by flow cytometry and qPCR. Six patients (35.2 %) experienced 12 Treatment Emergent Adverse Event (TEAE), 10 out of whom were infections, with grade 3-4 neutropenia (Table 2). We only recorded one death from SARS-Cov2 infection (Interstitial Pneumonia) in a patient in MRD-negative complete remission. There were no treatment-related deaths. Conclusion: In patients with CBFL, the regimen consisting of intensive chemotherapy and consolidation chemotherapy in association with Mido, followed by Mido maintenance, had an acceptable safety profile and excellent response rates with a significant proportion of patients in MRD-negative complete remission. Trial is continuing to accrue (EudraCT Number 2017-002094-18; ClinicalTrials ID: NCT 03686345). This work was supported by a grant from Fondazione Regionale per la Ricerca Biomedica (FRRB 2015). Disclosures Krampera: Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Todisco:Jannsen, Abbvie, Jazz: Membership on an entity's Board of Directors or advisory committees. Veronese:Novartis: Other: Travel Expenses; Bayer: Honoraria; AstraZeneca: Other: Travel Expenses; Janssen Cilag: Honoraria. OffLabel Disclosure: Midostaurin for treatment of Core Binding Factor Leukemia. The drug has been used as KIT inhibitor.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results